Catalyst Pharmaceuticals (CPRX) EBT (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly EBT of $84.2 million for Q1 2026, up 18.16% year-on-year from $71.3 million in Q1 2025, and up 17.15% on a QoQ basis from $71.9 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of EBT data on file, last reported at $84.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 18.16% year-over-year to $84.2 million; the trailing twelve-month figure through Mar 2026 stood at $296.5 million (up 14.7% YoY), and the FY2025 full-year result was $283.5 million, up 31.1% from the prior year.
- EBT for Q1 2026 stood at $84.2 million, up from $71.9 million in the prior quarter.
- Across five years, EBT topped out at $84.2 million in Q1 2026 and bottomed at -$38.0 million in Q3 2023.
- The 5-year median for EBT is $48.5 million (2023), against an average of $46.1 million.
- The widest annual swing landed in 2023, when EBT sank 246.2%; it then jumped 250.46% in 2024.
- A 5-year view of EBT shows it stood at $33.0 million in 2022, then surged by 41.5% to $46.7 million in 2023, then soared by 58.82% to $74.2 million in 2024, then slipped by 3.07% to $71.9 million in 2025, then grew by 17.15% to $84.2 million in 2026.
- The last three EBT figures came in at $84.2 million (Q1 2026), $71.9 million (Q4 2025), and $71.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 84.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.23 Mn |
| Dec 31, 2025 | 71.90 Mn |
| Sep 30, 2025 | 71.04 Mn |
| Jun 30, 2025 | 69.29 Mn |
| Mar 31, 2025 | 71.29 Mn |
| Dec 31, 2024 | 74.18 Mn |
| Sep 30, 2024 | 57.21 Mn |
| Jun 30, 2024 | 55.79 Mn |
| Mar 31, 2024 | 29.09 Mn |
| Dec 31, 2023 | 46.71 Mn |
| Sep 30, 2023 | -38.02 Mn |
| Jun 30, 2023 | 48.51 Mn |
| Mar 31, 2023 | 37.31 Mn |
| Dec 31, 2022 | 33.01 Mn |
| Sep 30, 2022 | 26.01 Mn |
| Jun 30, 2022 | 28.25 Mn |
| Mar 31, 2022 | 17.46 Mn |
| Dec 31, 2021 | 12.81 Mn |
| Sep 30, 2021 | 14.07 Mn |
| Jun 30, 2021 | 15.90 Mn |
| Mar 31, 2021 | 9.88 Mn |
| Dec 31, 2020 | 8.72 Mn |
| Sep 30, 2020 | 11.74 Mn |
| Jun 30, 2020 | 10.39 Mn |
| Mar 31, 2020 | 11.04 Mn |
| Dec 31, 2019 | 8.41 Mn |
| Sep 30, 2019 | 14.24 Mn |
| Jun 30, 2019 | 11.41 Mn |
| Mar 31, 2019 | -644,503.00 |
| Dec 31, 2018 | -14.50 Mn |
| Sep 30, 2018 | -7.84 Mn |
| Jun 30, 2018 | -5.97 Mn |
| Mar 31, 2018 | -5.70 Mn |
| Dec 31, 2017 | -5.39 Mn |
| Sep 30, 2017 | -4.18 Mn |
| Jun 30, 2017 | -3.88 Mn |
| Mar 31, 2017 | -4.97 Mn |
| Dec 31, 2016 | -4.16 Mn |
| Sep 30, 2016 | -3.95 Mn |
| Jun 30, 2016 | -4.57 Mn |
| Mar 31, 2016 | -5.39 Mn |
| Dec 31, 2015 | -5.82 Mn |
| Sep 30, 2015 | -4.45 Mn |
| Jun 30, 2015 | -4.56 Mn |
| Mar 31, 2015 | -5.41 Mn |
| Dec 31, 2014 | -3.49 Mn |
| Sep 30, 2014 | -5.01 Mn |
| Jun 30, 2014 | -3.20 Mn |
| Mar 31, 2014 | -3.81 Mn |
| Dec 31, 2013 | -1.35 Mn |
| Sep 30, 2013 | -5.91 Mn |
| Jun 30, 2013 | -3.14 Mn |
| Mar 31, 2013 | -1.74 Mn |
| Dec 31, 2012 | -76,585.00 |
| Sep 30, 2012 | -2.62 Mn |
| Jun 30, 2012 | -289,080.00 |
| Mar 31, 2012 | -1.09 Mn |
| Dec 31, 2011 | -2.35 Mn |
| Sep 30, 2011 | -1.13 Mn |
| Jun 30, 2011 | -1.39 Mn |
| Mar 31, 2011 | -1.52 Mn |
| Dec 31, 2010 | -728,754.00 |
| Sep 30, 2010 | -903,985.00 |